{"product_id":"exactsciences-bcg-matrix","title":"Exact Sciences Boston Consulting Group Matrix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eActionable Strategy Starts Here\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eCurious where Exact Sciences’ products land—Stars, Cash Cows, Dogs, or Question Marks? This snapshot hints at the story, but the full BCG Matrix lays it out quadrant by quadrant with crisp data and strategic moves you can act on. Buy the complete report for a Word narrative plus an editable Excel summary, clear recommendations, and a ready-to-use roadmap for where to invest, divest, or double-down. Get instant access and skip the guesswork.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etars\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCologuard (stool DNA CRC screening)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCologuard is Exact Sciences' flagship, category-defining stool-DNA CRC screen, generating roughly $1.6B of company revenue in 2023 and processing just over 1M tests annually into 2023–24; it continues to pull share from colonoscopy and FIT as CRC screening prevalence rises and primary care adoption grows. Heavy promotion and payer contracting remain important, but the commercialization flywheel is expanding the eligible screening pool—keep investing to cement leadership.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOncotype DX Breast Recurrence Score\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOncotype DX is the guideline-backed gold standard for early breast cancer decision support, listed in NCCN and ASCO guidelines and used in over 1 million patients globally. High clinical utility and entrenched oncologist behavior sustain steady demand and industry-leading margins, making it a cash-generating Stars asset. It requires periodic data refreshes and ongoing KOL engagement to defend the moat and fund next-wave R\u0026amp;D.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBrand trust + guideline inclusion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eExact’s credibility with major societies and payers accelerates adoption across launches, helping drive company revenue above $3 billion in 2024 and expanding Cologuard use to over 10 million screened patients to date. That stamp of approval converts slower-moving systems and large IDNs, shortening sales cycles and boosting lifetime value. It’s not a SKU, but it behaves like one: a reusable asset that compounds with each guideline or payer win. Keep investing in evidence and outcomes stories to sustain this multiplier effect.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntegrated screening experience (ordering, reminders, logistics)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eIntegrated screening experience (ordering, reminders, logistics) drives higher completion and market share; patient navigation and PCP workflow integration can boost screening completion by up to 20 percentage points per program evaluations. Operational ease is a competitive weapon that increases adherence and retention. Scale lowers per-test costs and deepens health-system stickiness. Keep tightening the loop from script to result.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eNavigation raises completion up to 20pp\u003c\/li\u003e\n\u003cli\u003eOperational ease = competitive moat\u003c\/li\u003e\n\u003cli\u003eScale reduces unit cost, increases stickiness\u003c\/li\u003e\n\u003cli\u003eTighten script-to-result loop\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eData moat and real‑world evidence engine\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eMassive volumes—over 2 million Cologuard tests annually in recent years—feed longitudinal real‑world evidence and iterative product tweaks, translating into stronger performance claims that shorten sales cycles and improve payer renewal rates. Competitors can replicate features but not the depth of longitudinal outcomes supporting clinical utility; relentless publishing (over 100 peer‑reviewed studies to date) widens the gap.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eData scale: 2M+ tests\/year\u003c\/li\u003e\n\u003cli\u003eEvidence depth: 100+ peer‑reviewed studies\u003c\/li\u003e\n\u003cli\u003eCommercial impact: faster sales cycles, stronger payer renewals\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTwo diagnostic leaders: billions in revenue, scale, evidence and payer momentum\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCologuard and Oncotype DX are Stars: Cologuard ≈$1.6B revenue (2023) with ~2M tests\/year and Exact Sciences revenue \u0026gt;$3B (2024). Oncotype DX serves 1M+ patients globally and delivers high margins. Scale, 100+ studies and payer\/guideline wins sustain growth; continue investing in evidence, navigation, and KOL engagement.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCologuard rev (2023)\u003c\/td\u003e\n\u003ctd\u003e$1.6B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTests\/yr\u003c\/td\u003e\n\u003ctd\u003e~2M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompany rev (2024)\u003c\/td\u003e\n\u003ctd\u003e$3B+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOncotype pts\u003c\/td\u003e\n\u003ctd\u003e1M+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eBCG Matrix of Exact Sciences: evaluates products as Stars, Cash Cows, Question Marks, Dogs with investment, hold, or divest guidance.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eOne-page Exact Sciences BCG Matrix: clear quadrant mapping to ease portfolio decisions and C-level reviews.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eash Cows\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOncotype DX Breast (mature geographies)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIn the U.S. and select EU markets Oncotype DX holds a dominant commercial position with high market share and modest growth as clinical use is routine in HR+\/HER2- early breast cancer and supported by ASCO\/NCCN guideline recommendations and TAILORx evidence.\u003c\/p\u003e\n\u003cp\u003eReimbursement remains stable across payers, utilization patterns are predictable, and sales and lab operations have achieved efficient unit economics, making Oncotype a steady cash generator for Exact Sciences that requires maintenance rather than blitz scaling.\u003c\/p\u003e\n\u003cp\u003eManagement focus should be on milking cash flows while defending guideline language and payer coverage to preserve long-term revenue durability rather than pursuing aggressive expansion.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOncotype DX Prostate\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOncotype DX Prostate is smaller than its breast counterpart but entrenched with urologists and tumor boards, addressing decision-making in a market with roughly 288,300 new US prostate cancer cases annually (2024 ACS estimate). The market is mature, driving incremental uptake rather than step-change volume. Solid margins come from scale, lab efficiency and cross-sell within Exact Sciences’ portfolio. Maintain tight coverage and deploy reps where conversion is highest to protect ROI.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOncotype DX Colon\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eOncotype DX Colon occupies a niche but steady role in adjuvant therapy decisions for stage II\/III colon cancer, with reliable reimbursement in eligible US patients as of 2024. It is not a growth rocket but generates recurring margin-supporting cash, enabling Exact Sciences to report 2024 total revenue of $4.16 billion while leveraging legacy oncology offerings. Low incremental investment is required to sustain clinical operations and lab capacity. Harvest cash and bundle the test within oncology contracting to improve deal economics.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEstablished payor contracts and IDN relationships\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eEstablished payor contracts and IDN relationships convert contracted lives into recurring, low-friction Cologuard volume; administrative load is predictable and appeal rates remain manageable, creating steady cash generation with limited upside. Maintain SLAs and pricing discipline to preserve margins and cash flow predictability.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRecurring volume: predictable contracted lives\u003c\/li\u003e\n\u003cli\u003eOperational: known admin load, manageable appeals\u003c\/li\u003e\n\u003cli\u003eStrategy: enforce SLAs and pricing discipline\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePreventionGenetics germline testing (select panels)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003ePreventionGenetics germline testing (select panels) sits as a cash cow for Exact Sciences: it leverages existing client relationships and lab scale to deliver steady low-single-digit revenue growth in 2024 while facing a mature, competitive market that limits upside. High lab throughput and panel bundling sustain gross margins above routine diagnostic averages, prompting menu optimization and retirement of low-margin SKUs to preserve profitability.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eOperational leverage with existing client base\u003c\/li\u003e\n\u003cli\u003eMature market → tame growth (low single-digit, 2024)\u003c\/li\u003e\n\u003cli\u003eThroughput + bundling → improved margins\u003c\/li\u003e\n\u003cli\u003eAction: optimize menus, retire low-margin SKUs\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOncotype DX, Cologuard and PreventionGenetics: cash-generating tests underpin \u003cstrong\u003e$4.16B\u003c\/strong\u003e revenue\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eOncotype DX breast and Cologuard function as Exact Sciences cash cows, delivering predictable margins and supporting corporate cash flow amid 2024 total revenue of 4.16 billion. Oncotype Prostate is entrenched with urologists in a US market of ~288,300 annual cases (2024 ACS). PreventionGenetics panels show low-single-digit growth in 2024 with above-average lab margins.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003eRole\u003c\/th\u003e\n\u003cth\u003e2024 metric\u003c\/th\u003e\n\u003cth\u003eGrowth\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eOncotype DX Breast\u003c\/td\u003e\n\u003ctd\u003ePrimary cash generator\u003c\/td\u003e\n\u003ctd\u003eSupports corporate cash flow (part of $4.16B)\u003c\/td\u003e\n\u003ctd\u003eModest\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOncotype DX Prostate\u003c\/td\u003e\n\u003ctd\u003eEntrenched\u003c\/td\u003e\n\u003ctd\u003eMarket ~288,300 cases\u003c\/td\u003e\n\u003ctd\u003eIncremental\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCologuard\u003c\/td\u003e\n\u003ctd\u003eRecurring volume\u003c\/td\u003e\n\u003ctd\u003eContracted lives, predictable\u003c\/td\u003e\n\u003ctd\u003eStable\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePreventionGenetics\u003c\/td\u003e\n\u003ctd\u003eMargin-supporting\u003c\/td\u003e\n\u003ctd\u003eLow-single-digit growth (2024)\u003c\/td\u003e\n\u003ctd\u003eLow\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eDelivered as Shown\u003c\/span\u003e\u003cbr\u003eExact Sciences BCG Matrix\u003c\/h2\u003e\n\u003cp\u003eThe file you're previewing for Exact Sciences is the exact BCG Matrix report you’ll receive after purchase. No watermarks, no placeholders—just the fully formatted, analysis-ready document. It’s crafted for clarity and immediate use in strategy or presentations. Buy once, download instantly, edit or print as needed.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"PortersFiveForce","offers":[{"title":"Default Title","offer_id":56163458875769,"sku":"exactsciences-bcg-matrix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0914\/5276\/8633\/files\/exactsciences-bcg-matrix.png?v=1762720377","url":"https:\/\/portersfiveforce.com\/products\/exactsciences-bcg-matrix","provider":"Porter's Five Forces","version":"1.0","type":"link"}